Stemline Therapeutics presents detailed SL-401 pivotal data in BPDCN
Stemline Therapeutics reported detailed data from its SL-401 pivotal trial in BPDCN, with results from other trials in additional indications. The trial enrolled 45 BPDCN patients and consisted of 3 Stages: Stage 1 (lead-in, dose escalation), Stage 2 (expansion), and Stage 3 (pivotal, confirmatory). December 13, 2017